MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine
*Biotechnology: Key Issues
*Key Terms: Biotechnology
Peptide
Parents
*Key Terms: Biotechnology
BioTechnology
Children
* Compounds based on biomimetics: non-peptide small molecule drug candidates and polymers that mimic natural activity
* Targeted Membrane disrupting peptides (MDPs)
*Amide Technologies offers on-demand complex peptide manufacturing at unprecedented speed.
*Antibody-conjugated nanoparticles that can be adapted to antigen peptides present in the bloodstream for the detection of diseases like tuberculosis and HIV
*Apellis Pharmaceuticals is an early stage drug development company focused on peptide drugs in the immunology space.
*Architects: Biotechnology _Monoclonal, Polyclonal, Bispecific Antibodies & Antibody-Drug Conjugates (ADC)s
*Architects: Biotechnology_Peptides
*Architects: Diabetes, Metabolic Disease, Dialysis, Renal & Kidney Companies (Pharmaceuticals, Biotechnology, Biosimilars)
*Architects: Drug Delivery
*Architects: Drug Delivery (Oral & Smart Pills)
*Architects: Endocrinology & Metabolic Diseases
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Migraine, Headache
*Architects: Obesity_Pharmaceuticals & Biotechnology
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
*Architects: Substance Abuse, Substance Use Disorder (SUD)_Opioid, Alcohol, Tobacco, Etc.
*Architects: Wound, Burn Care, Dressing and Infection Control
*Biotechnology company with a peptide drug discovery and development engine. that uses maskless chemical synthesis to synthesize and discover next-generation peptide therapeutics.
*Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc).
*Company's pipeline includes clearance of Neutrophil Extracellular Traps (NETs) downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes, for treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage due to sepsis.
*Decoy Therapeutics is a preclinical stage biotech company building a pandemic preparedness drug development platform using AI design of peptide ‘decoys’ that directly interfere with viral replication machinery.
*Dedicated to delivering oral peptide therapeutics
*Developing bone-targeting drug platform capable of precisely delivering small molecules, peptides, or large molecules directly to the site of broad bone fractures and disease designed to promote more rapid healing with fewer off-target safety concerns.
*DEVELOPS RNAI INTERFERENCE AND PEPTIDE DRUG CONJUGATES FOR A WIDE RANGE OF DISEASES.
*Enanta is a drug discovery company that morphs existing drugs, natural products and biologically-active peptide leads into small
*Funding: DOD_DTRA
*Gubra specializes in high-end preclinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases.
*i2o Therapeutics is a private biotechnology company that was founded in 2019 to exploit the versatile properties of ionic liquids for producing oral biologics and peptides.
*Industry: Indiana
*Industry: Michigan
*Lead candidate is GSBR-1290, a small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
*Lipogenyx™ is a breakthrough fat grafting technology based on a proprietary peptide hydrogel platform
*Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important
*MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders.
*Palatin Technologies Inc (PTN) - DEVELOPS PEPTIDE AND SMALL MOLECULE-BASED TREATMENTS FOR SEXUAL DYSFUNCTION, HEART FAILURE
*Pioneers: Alzheimer's Disease & Dementia
*Pioneers: Biotechnology_Peptides
*Pioneers: Infectious Diseases _ Antibiotics, Bacteriology
*Pioneers: Wound Care & Management
*Platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs.
*Precisely delivering RNA, DNA, and peptide cargoes to specific cellular targets, Organization & Developments: Flashpoint Therapeutics
*Proprietary phage display screening platform which directs the evolution of bicyclic peptides to rapidly and empirically generate optimized novel drug candidates
*Proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients.
*Specializes in peptide-based gastric inhibitory polypeptide receptor antagonists to monitor dietary-related metabolic diseases and decrease blood flow and lipid uptake in adipose tissue efficiently.
*The Boston-based startup is expected to use the proceeds to fund the clinical trials of its experimental peptide-based drugs, in
*The company develops peptide and small molecule cancer immunotherapeutic drug candidates.
*The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung
*The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
*The science behind bicycle peptides originated in the labs of the company’s co-founder Greg Winter, 2018 Nobel Prize winner British biochemist who is known for his work on monoclonal antibodies.
*Through its novel manufacturing platform developed at MIT, Amide is bridging the gap between traditional solid phase peptide synthesis and biological expression, empowering scientists on the cutting edge of peptide drug design.
*Vivtex has unique methods for oral delivery of biologics, such as proteins and peptides, which have historically required injection administration.
1) improving IGF-1 production via optimization of the signal peptide
1) Peptide Array for Identifying, Targeting, and Disrupting Specific Protein-protein Interactions
2) peptide-mediated protein knockdown technology that can compete with small molecule PROTAC technology in degrading proteins of interest and can replace antisense and siRNA technology platforms in many indications with greater specificity and greater temporal precision.
2007: Peptides to Nuetralize Heprin-Thomas Jefferson University
2019: Bicycle Therapeutics: Novel Bicycle Peptide Technology Could Disrupt The Monoclonal Antibodies Market_seekingalpha.com
2020: CREATIVE BIO-PEPTIDES and LEIDOS AWARDED US DOD CONTRACT
2020: FDA ranks the performance of 58 molecular coronavirus tests from major developers
2021: A data-driven approach towards generation of permeable peptide therapeutics _ RePORT 〉 RePORTER
2021: Creative Bio-Peptides Awarded $5.78 from NIH to Develop Breakthrough Treatments for Neuroinflammatory/Neurodegenerative Indications
2021: NASEM Panel_DRUG RESEARCH AND DEVELOPMENT FOR ADULTS ACROSS THE OLDER AGE SPAN
2021: NIDDK_Standardization of C-Peptide and HbA1C Measurements Program (U01 Clinical Trial Not Allowed)
2021: To date, the company has discovered more than 100 mitochondrial derived peptides and invented over 1,000 analogs.
2021: Vaxxinity IPO: Pioneering Vaccines For Chronic Diseases
2022: NIDDK_Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes (T1D) Research (U01 Clinical Trial Not Allowed)
2022: Peptide Delivered by Nasal Spray Can Reduce Seizure Activity and Protect Neurons in Alzheimer’s and Epilepsy_neurosciencenews
2022: Uses cell-penetrating peptides for mRNA delivery to cancer cells based on uptake and transfection capacity of Altamira's proprietary delivery platform, SemaPhore.
2022: With investment from Alloy, Boston peptide manufacturer announces Series A
2023: Amide Technologies Announces Complex Peptide Manufacturing Platform, Raises $16.5M to Expedite Frontier Drug Discovery
2024: Merck & Co. signs $220M macrocyclic peptide deal after hailing ‘next wave of drug discovery’
2024: Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
2024: Synthetic Peptide Reverses Alzheimer’s Symptoms_ neurosciencenews
2025: AI Designs Thousands of Peptides with Antibiotic Potential
2025: MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy
2025: Oculis' peptidomimetic helps protect eyes from optic nerve inflammation in phase 2
2025: The Internet Loves Peptide Therapy. Is It Really a Miracle Cure?
A Novel Approach to Peptide Labeling for the Imaging of Cancer by PET-University of California System: University of California, Davis
A Potent Peptide Adjuvant for Vaccines and Immunotherapies University of California System: University of California, San Diego Technology Transfer
A sprinkling of peptides designed to bind to the tumor cells make sure the particle’s payload reaches its target.
Aileron is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction target
Amphipathic Helical Glycopeptide Address Sequences for Enhanced Blood-Brain Barrier Transport of Neuroactive Peptides-University of Arizona
Anchor believes its pepducin approach--using short peptides bound to a hydrophobic lipid moiety--can penetrate to the receptor on the inner cell membrane, doing a much better job than most small molecules which target and modulate GPCR signaling.
Anemia
Antibacterial Peptides Active in Systemic Infections-Temple University
Antimicrobials
AriaVax vaccines are based on its proprietary peptide chemistry technology exclusively licensed by the Company from NIH
As well as the creation of new medicines from known pharmaceutically relevant peptides
Avacta Group Plc (AVCTF)
Based on technology from Purdue University, the company is advancing a suite of peptide therapeutics that target MAPKAP kinase 2 (MK2), a key terminal kinase in the TGF-beta/p38 pathway, with a high degree of specificity.
Bicycle Therapeutics plc (NASDAQ: BCYC)*
Biopharmaceutical company committed to the discovery, clinical development and marketing of small molecule and peptide therapeut
Biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeuti
Biopharmaceutical company utilizing novel chemistry to develop and commercialize human peptide-mimetic therapeutics
BioRexis' proprietary protein engineering technology provides novel protein and peptide drugs with superior pharmacology and Trans-bodies™ to replace conventional monoclonal antibodies.
BioRexis' technology involves fusion of peptides and proteins to a modified version of the blood serum protein transferrin, thereby prolonging their circulatory half-life, reducing dosage, improving efficacy and decreasing side effects.
BioSET spinal fusion product combines proprietary, bone stimulating peptide with a scaffold to induce bone formation
BioSET's synthetic peptides for tissue regeneration
Biotech is developing a human proinsulin C-peptide as a supplemental treatment for complications from type 1 diabetes.
Biotechnology company developing significant clinical applications for the peptide hormone, relaxin.
Biotechnology company focused on the identification and the development of novel, small molecule peptides for use in treating neurological, hematological, and immunological disorders.
Bladder tumor targeting peptides-Burnham Institute for Medical Research
Cationic lytic peptide (CLYPTM) technology platform
Could be used to deliver peptides, proteins and antibodies.
Creative Bio-Peptides, Inc.
design peptides that can neutralize the anticoagulant activities of heparin.
Develop Hemostatic Polymeric Wound Dressings Incorporating Concatameric Cationic Peptides
Developing novel peptide therapeutics using two platform technologies
Develops tailor-made peptide vaccines for Alzheimer ́s disease, Atherosclerosis, Parkinson ́s disease, Hypertension
Discovery of blood-borne low molecular weight peptidomic biomarkers for breast cancer detection-George Mason Intellectual Properties, Inc.
Discovery, identification and design of new peptide, polypeptide, protein and antibody compounds using our proprietary technology.
EEVs comprise small cyclic peptides chemically conjugated to any specific active biological therapeutic, and designed to act upon intracellular targets hitherto considered inaccessible and undruggable.
Encodia’s protein sequencing approach uses reverse-translation technology that turns peptide sequences into DNA, which can then be read by a DNA sequencer
Entrada is conjugating biologics to cell-penetrating peptides that induce endocytic uptake
Entrada Therapeutics, Inc. (NASDAQ:TRDA)*
Exsulin is a peptide-based drug in Phase II clinical trials that aims to regenerate insulin-producing islets in patients with TypeI diabetes.
First and only process that allows peptides to penetrate cells in a sequence-independent manner.
focuses on identifying and studying non-peptide, small molecular weight compounds likely to be orally effective as anthrax antit
Founded by Johns Hopkins University School of Medicine researchers, initially licensing their groundbreaking portfolio of vascular homeostatic peptides and technologies
Gains full-rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program
Gen2 platform, a portable peptide manufacturer
Genscript Biotech Corporation (OTCMKTS:GNNSF)
GLP-1 (Glucagon Like Peptide) -1
GPCRs (G protein-coupled receptors)
Heart homing peptides-Burnham Institute for Medical Research
HeMemics has a desiccation technology that can be applied to many peptides, proteins, cell types and possibly thin tissues.
Homing peptides to tumor lymphatic vasculature-Burnham Institute for Medical Research
Homing Peptides-Burnham Institute for Medical Research
HYD1 Peptides as Anti-Cancer Agents-University of Arizona
Incorporating its proprietary therapeutic peptides with medical devices to improve product performance, safety and patient well
Index Pledges €10M to New Company’s Development of Peptide Candidates for CNS Diseases (2010)
Insulin
Isogenica staff has expertise in many areas of peptide and protein engineering and display technologies.
Its products also include PuraMatrix synthetic peptide hydrogels that serve as a synthetic three-dimensional extracellular matrix cell culture gel
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications.
Mass spectrometry using peptide masses can identify as many as 20 proteins in minutes
Max Cynader CEO, PRIMARY PEPTIDES INC. (2021)
Merganser Biotech of Newtown Square, Pa., which is developing hepcidin peptides for the treatment of hemoglobinopathies such as sickle cell anemia and diseases of iron overload
Method of Using Opioid Peptide MMP-2200 for Treatment of Movement Disorders-University of Arizona
MicroCor® is designed for needle-free delivery of large molecules such as proteins and peptides
Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body.
Modular Peptide Binds to Biomaterials and Promotes New Bone Formation-Wisconsin Alumni Research Foundation (University of Wisconsin)
Molecular size peptides
MS/MS Peptide identification
NeuroScientific Biopharmaceuticals Ltd develops peptide-based drugs that target neurodegenerative conditions.
Novel Antimicrobial Peptide for the Treatment of Infectious Disease-University of Nebraska System
Novel peptide therapeutic for multiple sclerosis-Harvard University Office of Technology Development
Novel peptides to promote wound healing and neuroprotection-Children's Hospital Boston
Oral delivery of specific molecules or families of molecules, including parathyroid hormone (PTH), glucagon-like peptide (GLP)-1, GLP-2, human growth hormone (hGH), and others
Organ homing peptides-Burnham Institute for Medical Research
Osteoinductive peptides to enhance bone regeneration-Harvard University Office of Technology Development
PAD (Peripheral Artery Disease)
Palladio Biosciences is developing lixivaptan, an oral non-peptide, new chemical agent that works by selectively suppressing the activity of the hormone vasopressin at the V2 receptor, as a treatment for autosomal dominant polycystic kidney disease with the goal of slowing the progression of kidney function decline and avoiding the liver safety issues associated with tolvaptan.
Patch and applicator system for the delivery of therapeutic proteins, peptides and vaccines
Peptide Agonist of Akt Signaling-Washington University in St. Louis
Peptide Based Drug Development
Peptide Conjugates for Imaging and Treating Pancreatic Cancer-University of California System: University of California, Davis
Peptide Gene Transfer -UTHSC
Peptide Ligands-Arizona State University (AzTE)
Peptide mass fingerprinting
Peptide modification methods to repeatedly derive and develop novel and value-added therapeutic products
Peptide Scaffolds for Gene Transfer-University of Pennsylvania
Peptide treatments that can help repair damaged hearts by stimulating the development of cardiac muscle cells
Peptides for Delivery of Therapeutic and Diagnostic Drugs Across the Blood-Brain Barrier-Washington University in St. Louis
PeptiDream
Phylomer drug discovery platform for peptide-based drug discovery.
PolyMedix uses a rational drug design approach to create non-peptide small molecule drug candidates.
Polymer Compositions that Elicit a Strong and Sustained Antibody Response Against Encapsulated Synthetic Peptides-University of Michigan
Potent New Class of Opioid Peptide Analgesics-University of Arizona
Potential BlockBuster Technology and/or Business Model
Preclinical-stage biopharmaceutical company focused on peptides to modulate G-protein coupled receptors in oncology, CV and infl
Primary Peptides Inc.
Protein and peptide drugs with superior half-life and pharmacokinetic profiles.
Proteins will be rendered completent to enter cells by their being coupled (through genetic or chemical means) to small peptide
Psoriasis
PuraMatrix, a peptide hydrogel synthetic matrix material to create three-dimensional micro-environments for various cell culture and in vivo experiments, as well as for tissue regeneration, cell therapies, and drug delivery system applications
PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize Cell Penetrating Peptides (CPPs), a revolutionary delivery technology designed to overcome the major challenges of current gene-based therapies.
Rational Design and Engineering of Proteins And Peptides for Immunomodulation-Arizona State University (AzTE)
self-assembling peptide scaffolds
Targovax is an oncology biopharma company developing TG01, a peptide based active immunotherapy vaccine targeting pancreatic cancer.
The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).
The Company has an exclusive worldwide license from the Medical University of South Carolina (MUSC) for a proprietary peptide modification chemistry platform capable of improving the delivery and overall pharmacological profiles of peptide drugs.
The company has peptide technology which it is developing for a range of antimicrobial coating and therapeutic applications.
The company's lead product is a peptide fusion, currently in preclinical trials for Type 2 diabetes.
The company’s proprietary technology utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides.
The new company is focused on the development of a peptidic neurotrophic factor candidate NRG-101
The NIH announces its intention to reissue PAR-21-163 to solicit applications from researchers developing diverse biotherapeutic modalities — including but not limited to antibodies, peptides, proteins, oligonucleotides, gene therapies, cell therapies, and other emerging therapeutic modalities — for the treatment of nervous system and neuromuscular disorders.
The NIH announces its intention to reissue PAR-21-233 to solicit applications from researchers developing diverse biotherapeutic modalities — including but not limited to antibodies, peptides, proteins, oligonucleotides, gene therapies, cell therapies, and other emerging therapeutic modalities — for the treatment of nervous system disorders.
The RAS technology is based on oligosaccharide linked peptides that can redirect natural antibodies present in all humans to new targets.
The test uses mass spectrometry to measure the amounts of certain amyloid-β peptides floating in the bloodstream, as well as versions of the fat-binding protein apolipoprotein E, a common risk factor for Alzheimer’s.
These immunogenic peptides are active, novel, and unique, offering the potential of a universal hepatitis C vaccine against all genotypes.
This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).
Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/ glucose?dependent insulinotropic polypepide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of a
Tumor Detection by Targeting and Monitoring Integrin Expression Using Synergistic Effects of Molecular Beacons and Peptides-Washington University in St. Louis
Tumor targeting peptides-Burnham Institute for Medical Research
Tumor-penetrating peptides-Burnham Institute for Medical Research
Vaccines
Vaxxinity, Inc. (VAXX) is a clinical stage biotechnology company advancing its synthetic peptide vaccine platform (‘Vaxxine platform) that has the potential to enable a new class of therapeutics harnessing the human body’s innate immune system, to provide improved quality and convenience of care, increase availability of lower-cost treatments for a wide range of indications.
Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.
Wound and tumor homing peptides-Burnham Institute for Medical Research
Zosano is advancing a pipeline of drug candidates based on the ZP Patch Technology – a proprietary transdermal delivery technology capable of delivering peptides, proteins, small molecules and vaccines by permeating the skin’s outer layer